Does a lower HbA1c mean lower risk of heart disease? For people living with diabetes or prediabetes, this is one of the most clinically important questions to understand. HbA1c — a blood test reflecting average glucose levels over two to three months — is a key marker of both diabetes control and cardiovascular risk. While reducing elevated HbA1c can help protect the heart and blood vessels, the relationship is more nuanced than a simple equation. The type of medication used, how aggressively glucose is lowered, and the individual's broader risk profile all play a critical role in determining whether a lower HbA1c translates into genuine heart disease protection.

What HbA1c Measures and Why It Matters for Heart Health

HbA1c measures average blood glucose over 2–3 months; persistently elevated levels damage blood vessels through oxidative stress and inflammation, accelerating atherosclerosis and increasing cardiovascular disease risk.

HbA1c — or glycated haemoglobin — is a blood test that reflects your average blood glucose levels over the preceding two to three months. When glucose circulates in the bloodstream, it binds to haemoglobin (the protein inside red blood cells), forming glycated haemoglobin. The higher your blood sugar has been over that period, the higher your HbA1c result will be. In the UK, results are expressed in millimoles per mole (mmol/mol), though you may also see them quoted as a percentage.

As a general guide to UK thresholds: an HbA1c below 42 mmol/mol is considered normal; 42–47 mmol/mol indicates non-diabetic hyperglycaemia (NDH — sometimes called prediabetes); and 48 mmol/mol or above is used in the diagnosis of diabetes. These thresholds are set out in NHS and NICE guidance.

For people with type 1 or type 2 diabetes, HbA1c is one of the most important markers that clinicians monitor. Persistently elevated blood glucose causes damage to blood vessels through several mechanisms, including increased oxidative stress, inflammation, and the formation of advanced glycation end-products (AGEs). These processes accelerate atherosclerosis — the build-up of fatty plaques inside arterial walls — which is a primary driver of cardiovascular disease (CVD).

Because the heart and major blood vessels are particularly vulnerable to glucose-related damage, HbA1c has become a key indicator not just of diabetes control, but of broader cardiovascular risk. This is relevant not only to people already diagnosed with diabetes, but also to those with NDH or insulin resistance, where glucose dysregulation may already be silently affecting the cardiovascular system.

Important limitations of HbA1c HbA1c may give unreliable results in certain situations, including: anaemia or other conditions affecting red blood cell turnover; haemoglobin variants or haemoglobinopathies (such as sickle cell trait or thalassaemia); significant chronic kidney disease (CKD); recent blood transfusion; and pregnancy. In these circumstances, alternative measures — such as fructosamine or continuous glucose monitoring (CGM) — may be more appropriate. HbA1c is also not used to diagnose diabetes in children or during pregnancy. If you are unsure whether your HbA1c result is reliable, speak to your GP or diabetes care team.

In people with type 1 diabetes, CGM-derived metrics such as time-in-range are increasingly used alongside HbA1c to give a fuller picture of glucose control, as recommended in NICE guideline NG17.

Evidence Linking HbA1c Levels to Cardiovascular Risk

Evidence from UKPDS shows higher HbA1c is linked to greater cardiovascular events, but ACCORD, ADVANCE, and VADT trials found aggressive glucose lowering in high-risk patients offers limited macrovascular benefit and may increase mortality.

A substantial body of research supports the association between elevated HbA1c and increased cardiovascular risk. The UK Prospective Diabetes Study (UKPDS 33, 34, 35) demonstrated that higher HbA1c levels in people with type 2 diabetes were associated with greater rates of myocardial infarction, stroke, and cardiovascular mortality. Importantly, the UKPDS also showed a 'legacy effect' — a sustained reduction in cardiovascular events observed years after the intensive glucose-control arm of the trial ended, suggesting that early, sustained glucose control may confer long-term vascular protection.

However, the relationship is not entirely linear, and evidence from later trials has added important nuance. The ACCORD trial (NEJM, 2008) found that aggressively lowering HbA1c to below 42 mmol/mol (6.0%) in people with established cardiovascular disease or multiple risk factors was associated with increased mortality, despite achieving lower glucose levels. The ADVANCE (NEJM, 2008) and VADT (NEJM, 2009) trials similarly found limited macrovascular benefit from intensive glucose lowering in people with long-standing type 2 diabetes and high cardiovascular risk. Taken together, these trials highlight that the way HbA1c is lowered — and in whom — matters considerably.

More recent meta-analyses and cardiovascular outcome trials (CVOTs) suggest that:

• Each approximately 11 mmol/mol (1%) reduction in HbA1c is associated with a meaningful reduction in microvascular complications (such as kidney and eye disease); macrovascular benefit is less consistent and depends on the population and treatment used

• Cardiovascular benefit from glucose lowering appears most pronounced in people earlier in their disease course, with fewer comorbidities

• Certain glucose-lowering medications have demonstrated direct cardiovascular benefits that appear to go beyond their HbA1c-lowering effects: SGLT-2 inhibitors (such as empagliflozin in EMPA-REG OUTCOME, and dapagliflozin in DECLARE-TIMI 58) and GLP-1 receptor agonists (such as liraglutide in LEADER, and semaglutide in SUSTAIN-6 and REWIND) have each shown reductions in major adverse cardiovascular events in high-risk populations in large randomised trials. These findings are reflected in their licensed indications as assessed by the MHRA and EMA.

This distinction between the number on a blood test and the broader clinical picture is central to modern diabetes and cardiovascular care.

What the NHS and NICE Guidelines Say About HbA1c Targets

NICE NG28 recommends an HbA1c target of 48 mmol/mol for most adults with type 2 diabetes on non-hypoglycaemic therapy, with personalised targets based on age, frailty, and cardiovascular risk assessed using QRISK3.

NICE guidelines provide clear, individualised HbA1c targets rather than a single universal goal. The relevant guidelines are NICE NG17 (Type 1 diabetes in adults: diagnosis and management) and NICE NG28 (Type 2 diabetes in adults: management).

For most adults with type 2 diabetes managed with lifestyle changes or a single non-hypoglycaemic drug, NICE NG28 recommends an HbA1c target of 48 mmol/mol (6.5%). For those on medications that carry a risk of hypoglycaemia — such as sulphonylureas or insulin — the target is typically 53 mmol/mol (7.0%), to reduce the risk of dangerous low blood sugar episodes.

NICE emphasises that targets should be personalised. Factors such as age, frailty, life expectancy, the presence of established cardiovascular disease, and the individual's own preferences and capacity for self-management all influence what constitutes an appropriate target. For older or frailer patients, a more relaxed target may be clinically appropriate to avoid hypoglycaemia, which itself carries cardiovascular risk.

For cardiovascular risk assessment and lipid management, the current NICE guideline is NG238 (Cardiovascular disease: risk assessment and reduction, including lipid modification, 2023), which replaces the earlier CG181. NG238 recommends using the validated QRISK3 calculator to assess 10-year cardiovascular risk in adults with type 2 diabetes, ensuring that treatment decisions reflect the full clinical picture rather than focusing solely on glucose control. QRISK3 is not validated for use in type 1 diabetes; for people with type 1 diabetes, cardiovascular risk assessment and statin indications should follow NICE NG17 and NG238 separately.

The NHS Long Term Plan further stresses that HbA1c should be considered alongside other modifiable risk factors — including blood pressure, cholesterol, smoking status, and body weight — rather than in isolation.

When Lowering HbA1c May and May Not Reduce Heart Disease Risk

Lowering HbA1c most reliably reduces cardiovascular risk in people early in their diabetes course without established CVD; in long-standing diabetes, aggressive reduction can cause hypoglycaemia, which itself triggers cardiac risk.

The evidence suggests that lowering HbA1c is most likely to reduce cardiovascular risk in specific circumstances. People who are earlier in their diabetes journey — particularly those within the first decade of diagnosis, without established cardiovascular disease — appear to benefit most from intensive glucose control. In this group, preventing prolonged exposure to elevated glucose may slow the progression of atherosclerosis before significant vascular damage has occurred.

Conversely, in people with long-standing diabetes, established coronary artery disease, or multiple cardiovascular risk factors, aggressive HbA1c reduction does not consistently translate into fewer heart attacks or strokes, and may even cause harm if it leads to hypoglycaemia. Hypoglycaemic episodes trigger a stress response involving adrenaline release, which can provoke cardiac arrhythmias and increase the risk of acute cardiovascular events — a particular concern in those with pre-existing heart disease.

The choice of medication used to lower HbA1c is now considered as important as the target itself. In line with NICE NG28 (2022 update) and relevant NICE technology appraisals, clinicians should consider:

• SGLT-2 inhibitors (e.g., dapagliflozin, empagliflozin) for people with type 2 diabetes and established CVD, heart failure, or high cardiovascular risk, or those with CKD, given their proven heart and kidney protective effects

• GLP-1 receptor agonists (e.g., semaglutide, liraglutide) where weight loss and cardiovascular risk reduction are priorities, particularly in those with established CVD where a cardiovascular benefit has been demonstrated in outcome trials

• Avoiding medications with a high hypoglycaemia risk where possible in vulnerable individuals

If you are taking diabetes medication and experience side effects, you can report these to the MHRA via the Yellow Card Scheme (yellowcard.mhra.gov.uk). Do not stop any diabetes medicine suddenly without first seeking advice from your GP or diabetes care team.

In summary, a lower HbA1c may reduce heart disease risk, but this depends heavily on the individual's clinical context, how the reduction is achieved, and what other risk factors are present.

Other Factors That Affect Cardiovascular Risk Alongside HbA1c

HbA1c is one component of cardiovascular risk; blood pressure, cholesterol, smoking, kidney function, and body weight must all be managed simultaneously, as even well-controlled diabetes carries elevated cardiovascular risk.

It is important to understand that HbA1c is just one piece of a much larger cardiovascular risk puzzle. Even in people with well-controlled diabetes, cardiovascular risk remains elevated compared to the general population, which underscores the importance of addressing all modifiable risk factors simultaneously.

Key cardiovascular risk factors to manage alongside HbA1c include:

• Blood pressure: Hypertension is a major independent risk factor for heart disease and stroke. In line with NICE NG28 and NICE NG136 (Hypertension in adults), the general target for most people with diabetes is below 140/90 mmHg. A lower target of 130/80 mmHg may be appropriate for those with kidney disease, eye disease, or cerebrovascular damage. Targets may be adjusted in older adults; your GP can advise on what is right for you.

• Cholesterol: Elevated cholesterol accelerates atherosclerosis. NICE NG238 recommends offering atorvastatin 20 mg for primary prevention to adults with type 2 diabetes, with QRISK3 used to support shared decision-making. Dose escalation may be considered if needed. In the UK, non-HDL cholesterol is commonly used alongside LDL cholesterol to monitor treatment response.

• Smoking: Smoking dramatically amplifies cardiovascular risk in people with diabetes, and cessation support should be offered proactively.

• Body weight and physical activity: Excess visceral adiposity drives insulin resistance and inflammation. Even modest weight loss (5–10% of body weight) can meaningfully reduce cardiovascular risk.

• Kidney function: Diabetic kidney disease (nephropathy) is strongly associated with cardiovascular mortality. Regular monitoring of eGFR and urine albumin-to-creatinine ratio (ACR) is recommended, in line with NICE NG203 (Chronic kidney disease: assessment and management).

• Retinal screening: Annual diabetic eye screening is an important part of complication surveillance and is offered through the NHS Diabetic Eye Screening Programme.

Mental health also plays an underappreciated role — depression and chronic stress are associated with poorer diabetes self-management and worse cardiovascular outcomes. A holistic approach that addresses psychological wellbeing alongside physical health markers is consistent with best practice.

Talking to Your GP About HbA1c and Heart Health

Discuss your QRISK3 score, statin or antihypertensive need, and medication suitability with your GP; annual NHS diabetes reviews are the key opportunity to reassess all cardiovascular risk factors together.

If you have diabetes or have been told your HbA1c is elevated, it is worth having an open conversation with your GP or diabetes care team about what your result means for your heart health specifically. Rather than focusing solely on achieving a particular number, ask about your overall cardiovascular risk and what steps — beyond glucose control — might be most beneficial for you as an individual.

Questions worth raising with your GP include:

• What is my current QRISK3 score (if I have type 2 diabetes), and what does it mean for me?

• Should I be taking a statin or blood pressure medication alongside my diabetes treatment?

• Is my current diabetes medication the most appropriate choice given my cardiovascular risk profile?

• Am I due for kidney function, cholesterol, or eye screening checks?

When to seek urgent or emergency help If you experience symptoms that may suggest a heart attack — such as chest pain or tightness, pain spreading to the arm, neck or jaw, sudden breathlessness, or sweating — call 999 immediately. Similarly, if you or someone with you develops sudden facial drooping, arm weakness, or speech difficulty (the FAST signs of stroke), call 999 without delay. Do not wait and do not drive yourself to hospital. For urgent concerns that are not life-threatening, contact NHS 111 online or by phone.

Regular structured diabetes reviews — offered annually through the NHS — are an important opportunity to reassess HbA1c alongside blood pressure, cholesterol, kidney function, foot health, and retinal screening. Attending these reviews consistently, and engaging actively with your care team, is one of the most effective ways to reduce your long-term risk of heart disease. Managing cardiovascular risk is a collaborative process, and your GP can help tailor a plan that reflects your individual circumstances, preferences, and goals.

Frequently Asked Questions